We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

55 hedge funds and large institutions have $168M invested in NKGen Biotech, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $155M → $168M (+$12.7M)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

7% less funds holding

Funds holding: 59 → 55 (-4)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
55
Holders Change
-4
Holders Change %
-6.78%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
8
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$8.14M
2
PC
Periscope Capital
Ontario, Canada
+$4.6M
3
UOC
UBS O'Connor
Illinois
+$3.23M
4
KL
KIM LLC
Kansas
+$3.03M
5
KIM
Karpus Investment Management
New York
+$2.95M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$5.87M
2
CAC
Cowen and Company
New York
-$3.62M
3
TCA
Taconic Capital Advisors
New York
-$3.48M
4
JP Morgan Chase
JP Morgan Chase
New York
-$2.37M
5
EC
Elequin Capital
New York
-$2.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$13.7M – – –
PC
2
Periscope Capital
Ontario, Canada
$12.3M +$4.6M +456,046 +60%
MF
3
Magnetar Financial
Illinois
$9.95M -$174K -17,293 -2%
AC
4
Aristeia Capital
Connecticut
$8.17M +$8.14M +806,666 New
KL
5
KIM LLC
Kansas
$7.7M +$3.03M +300,000 +65%
CIM
6
Cowen Investment Management
New York
$7.6M +$2.02M +200,000 +36%
Balyasny Asset Management
7
Balyasny Asset Management
Illinois
$7.09M – – –
RCM
8
Radcliffe Capital Management
Pennsylvania
$7.06M +$92.4K +9,155 +1%
SIM
9
Sandia Investment Management
Massachusetts
$6.34M – – –
RCM
10
Rivernorth Capital Management
Florida
$5.14M – – –
CSS
11
Cubist Systematic Strategies
Connecticut
$5.12M -$105K -10,400 -2%
Jane Street
12
Jane Street
New York
$5.08M +$9.75K +966 +0.2%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
13
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$5.07M – – –
6CM
14
683 Capital Management
New York
$4.87M – – –
PSAMP
15
P. Schoenfeld Asset Management (PSAM)
New York
$4.05M – – –
Goldman Sachs
16
Goldman Sachs
New York
$3.7M – – –
CF
17
Cantor Fitzgerald
New York
$3.5M – – –
UOC
18
UBS O'Connor
Illinois
$3.24M +$3.23M +320,103 New
PAMP
19
Polar Asset Management Partners
Ontario, Canada
$3.04M – – –
FTCM
20
Fir Tree Capital Management
New York
$3.02M +$65.6K +6,506 +2%
KIM
21
Karpus Investment Management
New York
$2.96M +$2.95M +292,300 New
GCWM
22
Graham Capital Wealth Management
District of Columbia
$2.73M -$13K -1,289 -5%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$2.56M – – –
ETH
24
Exos TFP Holdings
New York
$2.53M -$723K -71,681 -22%
GF
25
Gabelli Funds
New York
$2.49M -$353K -35,000 -12%
1
2 3

NKGN Hedge Fund Activity: Q1 2023 in Review

55 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q1 2023, worth a combined $168M — up 8.2% from $155M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NKGN and 7 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 8 added.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $8.14M. The largest seller was Marshall Wace, exiting entirely with an estimated $5.87M sold.

  • 55 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q1 2023, down from 59 in Q4 2022.
  • Funds reported $168M of NKGen Biotech, Inc. Common Stock stock for Q1 2023, up 8.2% quarter-over-quarter.
  • 7 funds opened new NKGen Biotech, Inc. Common Stock positions in Q1 2023 and 10 closed out, a net change of -3 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q1 2023 was Aristeia Capital, an estimated $8.14M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q1 2023 was Marshall Wace, an estimated $5.87M sold.

Based on aggregated 13F filings for Q1 2023.